| Ranque Brigitte, MD, PhD | |
| 0033 1 56093331 | |
| [email protected] |
| Jean-Benoit Arlet, MD,PhD | |
| 0033 1 56093331 | |
| [email protected] |
2 France sites
> 18 Years
N/A
Interventional
All
Device
Other
Unknown
The primary goal of this randomized, controlled, open-label study is to determine the
efficacy of AccuveinV400 (a transillumination veins device) to facilitate peripheral
intravenous (IVP) catheter placement during a vaso-oclusive crisis. The investigators
hypothesized that the number of attempts to a successful placement of a peripheral IV, our
primary outcome, would be shorter with the assistance of the Accuvein V400. It is also
expected that AccuveinV400 will reduce the time of the procedure, the rate of failure, the
technique-related pain.
– Sickle cell patients (all genotypes)
– Patients hospitalized for uncomplicated vaso-occlusive crisis (CVO) in
Internal/general Medicine department
– Patients requiring the placement or replacement of a peripheral intra-venous catheter
in the Department of Internal/general Medicine
– Patients arrived in the internal/general medicine department of the hospital between
9h and 18h and except weekends
– Signed informed consent.
– Affiliated to the French health care insurance.
– Signs of shock
– Acute chest Syndrome
– Central venous catheter already present
– Indication to have a central venous catheter from the ourset
– Patient who has already participated to the PERFID study during the current
hospitalization
– Refusal of the patient’s participation
– Pregnant or lactating woman
– Patient under guardianship or curatorship